Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025CureusOpen Access

Novel Therapies in Advanced Pancreatic Cancer: A Peak Beyond the Realms of Gene Targeting

View Full Paper
Ask AI
Bookmark
Share

Authors

PDPrashil DaveVBVishal BeriwalaCPCharmy Parikh

Discussion

Loading...

Member takes

Overview

Literature review reveals innovative therapies improving outcomes in pancreatic cancer, suggesting novel targeting strategies.

Key Points

  • Advanced pancreatic cancer shows a five-year survival rate of only 6-8%, highlighting the need for new strategies.
  • In clinical trials, mFOLFIRINOX and gemcitabine-nab-paclitaxel both show comparable overall survival rates of ~23-25 months.
  • Recent advancements in precision therapy targeting actionable mutations may enhance treatment efficacy significantly.
  • Bispecific antibodies and metabolic interventions are undergoing evaluation, revealing potential in improving therapeutic outcomes.

Cite This Study

Dave et al. (2025) studied this question.

synapsesocial.com/papers/68c23e02b210217d64790295https://doi.org/10.7759/cureus.89054
View Full Paper
Ask AI
Bookmark
Share